Siren Biotechnology and Catalent Inc. entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent will further support process optimization at its process and clinical development center in Baltimore, MD.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.5 USD | +3.06% | +1.84% | +25.75% |
May. 29 | Catalent Shareholders Approve Deal With Novo Holdings | MT |
May. 29 | Catalent stockholders approve deal with Novo Holdings | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.75% | 9.92B | |
+51.63% | 798B | |
+41.51% | 633B | |
-5.10% | 356B | |
+19.90% | 328B | |
+9.95% | 304B | |
+17.66% | 244B | |
+3.39% | 227B | |
+10.75% | 216B | |
+6.99% | 166B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer